Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
NEWARK, Calif., Aug. 28, 2017 -- Depomed Inc. (NASDAQ:DEPO) today announced that it has been selected to join the Collaborative for Effective Prescription Opioid Policies (CEPOP) a diverse group of over 70 stakeholders creating and advancing policies and educational initiatives aimed at reducing opioid abuse and promoting treatment options for those living with pain or confronting addiction.
“We are pleased to be joining a well-respected organization that shares our commitment to reducing prescription opioid misuse as well as highlighting the ethical and responsible prescribing and use of treatment options for those living with pain,” said Arthur Higgins, President and Chief Executive Officer of Depomed. “We look forward to engaging with this unique group of patient, family advocacy, public health, prescriber, research and supply chain organizations to develop and implement strategies to address responsible opioid use while recognizing the needs of patients in pain. At Depomed, it is clear to us that tackling these issues requires collaboration among all stakeholders, and we view this partnership with CEPOP as an important addition to our ongoing and future activities aimed at highlighting the responsible prescribing and use of opioids.”
About the Collaborative for Effective Prescription Opioid Policies (CEPOP)
Launched in January of 2015, the Collaborative for Effective Prescription Opioid Policies (CEPOP) brings together a broad array of stakeholders interested in reducing opioid medication abuse, misuse, and diversion. Specifically, CEPOP supports a comprehensive and balanced public policy agenda that reduces abuse and promotes treatment options, both for those living with pain and confronting addiction. CEPOP’s advocacy is focused on driving actions in the public sector that develop and deploy evidence-based solutions to these challenges. For more information visit https://cepoponline.org/
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
